Novartis
C.H. Smorenburg
Novartis
Randomization in 2:1 ratio: Arm A: Exemestane 25 mg/day p.o. + everolimus 5 mg x 2/day p.o. Arm B: Exemestane 25 mg/day p.o. + placebo x 2/day p.o
To compare the combination treatment of everolimus and exemestane to exemestane alone with respect to progression-free survival in postmenopausal women with estrogen receptor positive breast cancer that is refractory to non steroidal aromatase inhibitors(NSAIs).
Primary endpoint:
Secondary endpoints:
Postmenopausal women with locally advanced or metastatic ER positive breast cancer refractory to non steroidal aromatase inhibitors (NSAIs)
